Multiple Endocrine Neoplasia Type 1 Market

Market Overview:

The 7 major multiple endocrine neoplasia type 1 markets reached a value of USD 1,814.2 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 3,739.0 Million by ​2035​, exhibiting a growth rate (CAGR) of 6.80% during 2025-2035.

The multiple endocrine neoplasia type 1 market has been comprehensively analyzed in IMARC's new report titled "Multiple Endocrine Neoplasia Type 1 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Multiple endocrine neoplasia type 1 is an uncommon disorder. It primarily forms tumors in the glands that produce and secrete hormones. These are known as the endocrine glands. The disease can potentially lead to cancers in the small intestine and stomach. Symptoms of multiple endocrine neoplasia type 1 vary from person to person, depending on the afflicted glands and tumor type. Some common indications include fatigue, bone pain, enlargement of the bones, kidney stones, stomach ulcers, muscle weakness, depression, acid reflux, diarrhea, etc. Individuals suffering from this ailment might also experience vision changes, such as double vision or decreased peripheral vision. The disorder is primarily diagnosed clinically based on the presence of characteristic symptoms, family history, and physical examination. The healthcare professional may also perform magnetic resonance imaging (MRI), which uses a magnetic field and radio waves to make images of the organs and tissues in the body. In some cases, genetic screening tests may need to be performed to detect genetic changes known to be associated with multiple endocrine neoplasia type 1.

The escalating prevalence of mutations in the MEN1 gene that controls the production of menin, a protein that stops cells from growing and dividing too fast, is primarily driving the multiple endocrine neoplasia type 1 market. In addition to this, the inflating utilization of somatostatin analogues to help manage symptoms by suppressing the secretion of hormones produced by the tumors associated with MEN1 is also creating a positive outlook for the market. Moreover, the widespread adoption of Ga-DOTATATE PET scan, since it can effectively detect small neuroendocrine tumors throughout the body, including in the pancreas, pituitary gland, and parathyroid glands, is further bolstering the market growth. Apart from this, the rising usage of radiofrequency ablation on account of its several benefits, like faster recovery time, reduced complications, and improved quality of life for suitable patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which aims to treat the condition by replacing the mutated MEN1 gene with a functional copy, is expected to drive the multiple endocrine neoplasia type 1 market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the multiple endocrine neoplasia type 1 market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for multiple endocrine neoplasia type 1 and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple endocrine neoplasia type 1 market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the multiple endocrine neoplasia type 1 market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the multiple endocrine neoplasia type 1 market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current multiple endocrine neoplasia type 1 marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the multiple endocrine neoplasia type 1 market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the multiple endocrine neoplasia type 1 market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the multiple endocrine neoplasia type 1 market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of multiple endocrine neoplasia type 1 across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of multiple endocrine neoplasia type 1 by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of multiple endocrine neoplasia type 1 by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with multiple endocrine neoplasia type 1 across the seven major markets?
• What is the size of the multiple endocrine neoplasia type 1 patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of multiple endocrine neoplasia type 1?
• What will be the growth rate of patients across the seven major markets?

Multiple Endocrine Neoplasia Type 1: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for multiple endocrine neoplasia type 1 drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple endocrine neoplasia type 1 market?
• What are the key regulatory events related to the multiple endocrine neoplasia type 1 market?
• What is the structure of clinical trial landscape by status related to the multiple endocrine neoplasia type 1 market?
• What is the structure of clinical trial landscape by phase related to the multiple endocrine neoplasia type 1 market?
• What is the structure of clinical trial landscape by route of administration related to the multiple endocrine neoplasia type 1 market?